share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Feb 1 06:49
Summary by Futu AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a stock transaction involving the sale of 50,000 common shares on January 29, 2024. The shares were sold at prices ranging from $60.5031 to $61.0998, resulting in a total market value of $3,025,572.69. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at a price of $19.12 per share. Following the transactions, Kulkarni directly holds 187,377 common shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.